JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Expression levels of STAT3, and protein levels of IL‑6 and sPD‑L1 in different pathological characteristics of endometrial adenocarcinomas

  • 0Department of Gynecology and Obstetrics, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei 075000, P.R. China.
Oncology Letters +

|

February 6, 2025

|

February 6, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Levels of interleukin-6 (IL-6), signal transducer and activator of transcription 3 (STAT3), and soluble programmed death ligand 1 (sPD-L1) are elevated in endometrial adenocarcinoma (EA). Higher levels correlate with advanced disease, poor differentiation, and worse prognosis, aiding clinical evaluation.

Area Of Science

  • Gynecologic Oncology
  • Cancer Biomarkers
  • Molecular Pathology

Background

  • Endometrial adenocarcinoma (EA) is a prevalent cancer in women.
  • Identifying reliable biomarkers for staging and grading EA is crucial for patient management.
  • Signal transducer and activator of transcription 3 (STAT3), interleukin-6 (IL-6), and soluble programmed death ligand 1 (sPD-L1) are implicated in cancer progression.

Purpose Of The Study

  • To assess the expression levels of STAT3, IL-6, and sPD-L1 in patients with EA.
  • To investigate the association between these markers and various pathological characteristics of EA.
  • To evaluate the potential of these markers in predicting disease prognosis.

Main Methods

  • Retrospective analysis of 90 EA patients and 30 patients with atypical endometrial hyperplasia.
  • Comparison of STAT3, IL-6, and sPD-L1 levels based on differentiation degree, disease stage, myometrial invasion, and lymph node metastasis.
  • Correlation analysis between marker levels and patient prognosis.

Main Results

  • IL-6, STAT3, and sPD-L1 levels were significantly higher in EA patients compared to controls (P<0.001).
  • Elevated levels of these markers were significantly associated with poor differentiation, advanced disease stage, deeper myometrial invasion, and lymph node metastasis (P<0.001).
  • Higher marker levels correlated with a poorer prognosis (P<0.001).

Conclusions

  • STAT3, IL-6, and sPD-L1 expression is upregulated in EA and associated with adverse pathological features.
  • These biomarkers may serve as valuable tools for evaluating EA progression and predicting patient outcomes.
  • Clinical monitoring of IL-6, STAT3, and sPD-L1 levels could enhance disease assessment and prognosis prediction in EA.

Keywords: